目的 探讨荷丹片联合苯扎贝特片治疗高脂血症的临床疗效。方法 选取西安市第一医院2016年9月—2017年9月收治的175例高脂血症患者作为研究对象，将患者随机分为对照组（87例）和治疗组（88例）。对照组患者口服苯扎贝特片，1片/次，3次/d；治疗组患者在对照组治疗的基础上口服荷丹片，2片/次，3次/d。两组患者均连续治疗8周。观察两组患者的临床疗效，比较两组治疗前后的血脂、颈动脉内膜中层厚度（IMT）、内皮素-1（ET-1）、人前蛋白转化酶枯草溶菌素-9（PCSK9）水平。结果 治疗后，对照组和治疗组的总有效率分别为86.21%、96.59%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者总胆固醇（TC）、三酰甘油（TG）水平显著降低，载脂蛋白A1（APOA1）水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组患者TC、TG水平显著低于对照组，APOA1水平显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者IMT、ET-1水平显著降低，PCSK9水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组IMT、ET-1水平显著低于对照组，PCSK9水平显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 荷丹片联合苯扎贝特片治疗高脂血症疗效显著，安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Hedan Tablets combined with Bezafibrate Tablets in treatment of hyperlipidemia. Methods Patients (175 cases) with hyperlipidemia in Xi'an No. 1 Hospital from September 2016 to September 2017 were randomly divided into control (87 cases) and treatment (88 cases) groups. Patients in the control group were po administered with Bezafibrate Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Hedan Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the levels of blood lipid, IMT, ET-1, and PCSK9 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 86.21% and 96.59%, respectively, and there were differences between two groups (P<0.05). After treatment, the TC and TG levels in two groups were significantly decreased, but the APOA1 levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, TC and TG levels in the treatment group were lower than those in the control group, but APOA1 was higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, the IMT and ET-1 levels in two groups were significantly decreased, but the PCSK9 levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, IMT and ET-1 levels in the treatment group were lower than those in the control group, but PCSK9 was higher than those in the control group, and there were differences between two groups (P<0.05). Conclusion Hedan Tablets combined with Bezafibrate Tablets has clinical curative effect in treatment of hyperlipidemia, with good safety, which has a certain clinical application value.